Buy, sell or hold after Lilly’s Alzheimer’s flop?
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
Diseases
Articles
Failure of Lilly’s Alzheimer’s drug not a big surprise to analysts
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren’t shocked by the setback.
Lilly cancer drug lands accelerated FDA approval
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Purdue startup focuses on prostate cancer therapy
Research developed at Purdue University and licensed by a biomedical startup could give patients with late-stage prostate cancer an alternative to hormone therapies that can develop resistance after prolonged use.
Lilly pledges $90 million to improve global drug access
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
Indy firm specializing in prescription discounts plans to hire 230
Rx Help Centers, which helps insured and uninsured patients extract discounts on brand-name and generic drugs, has grown rapidly since shifting its focus from individuals to employers last year.
IU, Jackson Lab getting $25M to study Alzheimer’s Disease therapies
The National Institute on Aging is awarding $25 million to the Alzheimer's Disease Precision Models Center, a joint project of the Indiana University School of Medicine in Indianapolis and The Jackson Laboratory in Bar Harbor.
Big drug firms eye potential $7.2B animal vaccine market
Companies like Eli Lilly and Co. unit Elanco are focused on developing vaccines as alternatives to antibiotics.
Lilly stock rises after FDA panel backs new Jardiance label
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
IU to hire 40 faculty, spend up to $120M on new initiative
The money will be awarded from IU’s Grand Challenges Program, a new push that is designed to tackle “major and large-scale problems facing humanity” that can only be addressed by multidisciplinary research teams.
Biotech firm lands funding for cancer targeting
Animated Dynamics Inc. has raised $1.7 million in early funding to help it get its technology to market.
Merck, Pfizer double size of diabetes drug study to catch rivals
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
Indiana sees 70 percent surge in syphilis cases
State health officials are urging Indiana's health care providers to aggressively test patients for syphilis.
CEO Lechleiter says Lilly in ‘most prolific period of new launches’
The Indianapolis-based drugmaker said Tuesday it has built a robust pipeline of drugs that “has the potential” to launch 20 new products in the 10 years between 2014 and 2023.
Indiana Blood Center sees fewer donations amid Zika virus
The Indiana Blood Center said it has been forced to defer up to 30 percent of donors at some post-spring break blood drives because they had traveled to areas where the Zika virus is being transmitted.
Zika virus fear fuels demand for local DEET manufacturer
Indianapolis-based chemical manufacturer Vertellus Specialties Inc. has expanded its production capacity by 80 percent to keep up with customer demand for DEET, a common active ingredient in mosquito and tick repellents.
Bristol-Myers drug tops Lilly’s Erbitux in cancer study
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
Insulin’s surging price turns diabetes staple into luxury good
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
Time to cheer on the struggling YMCA
The national not-for-profit organization, trying to fight back against high-end gyms and boutique studios, is now a national model for diabetes prevention.
UPDATE: Lilly shares fall after it changes goal for Alzheimer’s trial
Shares in Eli Lilly and Co. fell Tuesday on concerns surrounding the potential approval of a drug designed to treat dementia caused by Alzheimer's disease.